US5393785A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Therapeutic antiestrogens
Assignee: Endorecherche Inc
•
Filing: 1992-07-14
•
Granted: 1995-02-28
•
Expires: 2012-07-14
Abstract
Abstract Novel antiestrogenic compounds are disclosed for use in therapeutic preparations for treatment of estrogen-dependent diseases. The compounds are specified diphenylethane and diphenylethylene analogs which show strong affinity for estrogen receptors but substantially lack the capacity to activate such receptors or otherwise act as agonists.
Inventors
- 👤 Fernand Labrie
- 👤 Yves Merand
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 12:30
CPC Classifications
C; C07; C07J; C07J71/00; C07J71/0005; C07J71/001; C07J71/0021; A; A61; A61K; A61K31/00; A61K31/095; A61K31/10; A61K31/13; A61K31/135; A61K31/138; A61K31/16; A61K31/165; A61K31/33; A61K31/38; A61K31/382; A61K31/395; A61K31/40; A61K31/4025; A61K31/435; A61K31/44; A61K31/445; A61K31/4523; A61K31/453; A61K31/4535; A61K31/47; A61K31/4709; A61K31/472; A61K31/4725; C07C; C07C235/00; C07C235/02; C07C235/32; C07C235/34; C07D; C07D235/00; C07D235/02; C07D235/04; C07D235/18; C07J1/00; C07J1/0003; C07J1/0011; C07J1/0018; C07J1/0022; C07J1/0025; C07J1/0051; C07J1/0055; C07J1/0059; C07J1/0066; C07J1/007; C07J1/0074; C07J1/0081; C07J1/0088; C07J1/0096; C07J17/00; C07J21/00; C07J21/005; C07J21/006; C07J21/008; C07J41/00; C07J41/0033; C07J41/0072; C07J41/0094; C07J51/00; C07J53/00; C07J53/002; C07J53/004; C07J53/008
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
131 words
A pharmaceutical composition comprising a pharmaceutically acceptable diluent or carrier and a therapeutically effective amount of an antiestrogen of the formula: ##STR15## wherein R 6 is methyl or ethyl; where the dotted line represents an optional double bond of configuration; wherein A 1 and A 11 are the same or different and are either absent or selected from the group consisting of straight-chain alkylene and branched-chain alkylene, A 1 and A 11 together having a total of from 3 to 20 carbon atoms; wherein Y is phenylene; wherein R 21 is selected from the group consisting of hydrogen, straight or branched-chain lower alkyl, lower alkenyl, and lower alkynyl, wherein X is CONR 23 , R 23 being hydrogen or lower alkyl; and wherein μ is an integer from 0 to 5.
Claim 2
Dependent Claim
131 words
A pharmaceutical composition comprising a pharmaceutically acceptable diluent or carrier and a therapeutically effective amount of an antiestrogen of the formula: ##STR15## wherein R 6 is methyl or ethyl; where the dotted line represents an optional double bond of configuration; wherein A 1 and A 11 are the same or different and are either absent or selected from the group consisting of straight-chain alkylene and branched-chain alkylene, A 1 and A 11 together having a total of from 3 to 20 carbon atoms; wherein Y is phenylene; wherein R 21 is selected from the group consisting of hydrogen, straight or branched-chain lower alkyl, lower alkenyl, and lower alkynyl, wherein X is CONR 23 , R 23 being hydrogen or lower alkyl; and wherein μ is an integer from 0 to 5.
Claim 3
Dependent Claim
23 words
A pharmaceutical composition comprising a pharmaceutically acceptable diluent or carrier and a therapeutically effective amount of an antiestrogen having the molecular formula: ##STR16##
Claim 4
Dependent Claim
23 words
A pharmaceutical composition comprising a pharmaceutically acceptable diluent or carrier and a therapeutically effective amount of an antiestrogen having the molecular formula: ##STR16##
Claim 5
Dependent Claim
117 words
An antiestrogenic compound having the molecular formula: ##STR17## wherein R 6 is methyl or ethyl; where the dotted line represents an optional double bond of configuration; wherein A 1 and A 11 are the same or different and are either absent or selected from the group consisting of a straight- or branched-chain alkylene, A 1 and A 11 together having a total of from 3 to 20 carbon atoms; wherein Y is phenylene; wherein R 21 is selected from the group consisting of hydrogen, straight or branched-chain lower alkyl, lower alkenyl, and lower alkynyl wherein X is --CONR 23 --, R 23 being hydrogen or lower alkyl; and wherein μ is an integer from 0 to 5.
Claim 6
Dependent Claim
117 words
An antiestrogenic compound having the molecular formula: ##STR17## wherein R 6 is methyl or ethyl; where the dotted line represents an optional double bond of configuration; wherein A 1 and A 11 are the same or different and are either absent or selected from the group consisting of a straight- or branched-chain alkylene, A 1 and A 11 together having a total of from 3 to 20 carbon atoms; wherein Y is phenylene; wherein R 21 is selected from the group consisting of hydrogen, straight or branched-chain lower alkyl, lower alkenyl, and lower alkynyl wherein X is --CONR 23 --, R 23 being hydrogen or lower alkyl; and wherein μ is an integer from 0 to 5.
Claim 7
Dependent Claim
8 words
An antiestrogenic compound having the molecular formula: ##STR18##
Claim 8
Dependent Claim
8 words
An antiestrogenic compound having the molecular formula: ##STR18##
References Cited (Backward Citations)
US3396169A
Cited
US4338122A
Cited
US5098903A
Cited
US4358461A
Cited
US4382094A
Cited
US4732912A
Cited
US4904661A
Cited
US4659516A
Cited
EP0138504A2
Cited
US4751240A
Cited
WO1990010462A1
Cited
WO1991017749A1
Cited
EP0470310A1
Cited
WO1992021669A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-02-27 | 1998-08-29 | 1999-02-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-02-27 | 2002-08-29 | 2003-02-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-02-27 | 2006-08-29 | 2007-02-28 | $7700.00 | Window Closed / Lapsed |